Multinational pharmaceutical and biotech company Pfizer and AI-powered data company Tempus announced a multiyear strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology. Pfizer will leverage Tempus' library of de-identified data to accelerate therapeutic development in oncology. It will also use Tempus' AI-driven companion diagnostic offerings and clinical trial-matching program to support therapeutic research and development. "Pfizer shares our commitment to bringing novel treatments to patients faster, and we look forward to working together to usher in the next generation of oncology therapeutics," Eric Lefkofsky, founder and CEO of Tempus, said in a statement. "This is the third strategic collaboration Tempus has established with a global pharmaceutical leader in the last year, as we believe that combining our technological capabilities with pharma's deep R&D expertise will get us much closer in realizing the full potential of precision medicine."

Tempus, a leader in artificial intelligence and precision medicine, announced a prospective study, in collaboration with AstraZeneca, that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca's Personalize SCLC Initiative and is currently open for enrollment. "This type of early-stage, prospective study is only possible when combining Tempus' comprehensive sequencing capabilities, multimodal database, and just-in-time clinical trial network." In the United States, lung cancer is the second most common cancer, and approximately 13% of people diagnosed with lung cancer have SCLC, according to the American Cancer Society. SCLC is an aggressive disease characterized by rapid growth, early metastasis, and acquired therapeutic resistance in which there is a high unmet need for therapeutic targets.

Recent advancements in underlying technology have finally made it possible for AI to impact clinical care in a meaningful way. Tempus' proprietary platform connects an entire ecosystem of real-world evidence to deliver real-time, actionable insights to physicians, providing critical information about the right treatments for the right patients, at the right time. Tempus is executing on the mission to create the world's largest, integrated dataset of molecular and clinical data. At Tempus, products are owned and developed by small, autonomous teams composed of developers, designers, data scientists, and product managers. You and your team set the goals, build the software, deploy the code, and contribute to a growing software platform that will make a lasting impact in the field of cancer research and treatment.

We decided that this topic is worth covering in depth since any changes to the healthcare system directly impact business leaders in multiple facets such as employee insurance coverage or hospital administration policies. Industry analysts estimate that the AI health market is poised to reach $6.6 billion by 2021 and by 2026 can potentially save the U.S. healthcare economy $150 billion in annual savings. However, no sources have taken a comprehensive look at machine learning applications at America's leading hospitals. This article aims to present a succinct picture of the implementation of machine learning by the five leading hospitals in the U.S. based on the 2016-2017 U.S. News and World Report Best Hospitals Honor Roll rankings. Through facts and figures we aim to provide pertinent insights for business leaders and professionals interested in how these top five US hospitals are being impacted by AI.

Combine data from EMR's, observational notes, claims and other databases at the patient level for analysis. Deliver advanced analysis of real world and clinical data to discover new research opportunities, run clinical trial simulations, perform endpoint (e.g.

The Molecular Twin initiative also will advance cancer care and research in underserved populations and enable investigators to analyze how ethnic and racial disparities affect tumor biology and treatment among diverse populations. The Molecular Twin database will integrate and store "de-identified" clinical and molecular patient information to ensure that patients and their physicians have access to individualized cancer care strategies, risk assessments, treatments and novel clinical trials. This patient information-stripped of personal details-also will be available to researchers to offer insight into why some patients are resistant to certain therapies and provide data for potential cancer discoveries, including new treatments. "Molecular twins serve as scientific stunt doubles that are always in the lab, ready to identify the best current therapies and, perhaps, reveal important details of how a cancer will affect the patient," said Dan Theodorescu, MD, PhD, director of Cedars-Sinai Cancer, who conceived of and leads the initiative. "We hope that in the long term, the scientific convergence of multiple biologic, physical and computational datasets on thousands of patients will enable us to develop the treatments of tomorrow as we discover the circuitry used by cancer and other abnormal cells to drive the disease.

A team of scientists from Geisinger and Tempus have found that artificial intelligence can predict risk of new atrial fibrillation (AF) and AF-related stroke. Atrial fibrillation is the most common cardiac arrhythmia and is associated with numerous health risks, including stroke and death. The study, published in Circulation, used electrical signals from the heart--measured from a 12-lead electrocardiogram (ECG)--to identify patients who are likely to develop AF, including those at risk for AF-related stroke. "Each year, over 300 million ECGs are performed in the U.S. to identify cardiac abnormalities within an episode of care. However, these tests cannot generally detect future potential for negative events like atrial fibrillation or stroke," said Joel Dudley, chief scientific officer at Tempus.

In the near future, MDs could get new helpful assistants, i.e. efficient multipurpose artificial intelligence (AI) algorithms that will assist them in examining and diagnosing patients, choosing the best treatment strategy, processing patients' requests, and keeping medical records. Currently, there are technologies that support physicians at every stage of treatment. Let's see how AI helps doctors in outpatient practice. One of the promising areas in outpatient practice is the introduction of chatbots. AI will quickly collect and analyze general symptoms of the condition, and then schedule an appointment with the right MD.

The world seems more divided today than ever, whether we're talking about politics or the questionable art form of twerking. However, there's one thing we can all agree on: cancer sucks. Nearly 40% of us will receive the dreaded diagnosis at some point in our lives, according to the National Cancer Institute. That's one reason why we've spent quite a bit of time writing about the topic, particularly the different technologies being developed to detect various forms of the disease. It's really a no-brainer: Data from Cancer Research UK suggests 80% of patients survive for at least 10 years after being diagnosed in the early stages of eight of the most common cancers.

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an advisor to Tempus and its leadership team, leveraging his vast experience as a medical policy expert and public health advocate to support Tempus as it harnesses the power and promise of big data and artificial intelligence to personalize patient care. Dr. Gottlieb most recently served as the 23rd Commissioner of the Food and Drug Administration (FDA), where he focused on developing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding patient choice and safety. Previously, he also served as the agency's Deputy Commissioner for Medical and Scientific Affairs and as a Senior Advisor to the FDA Commissioner. During his time as a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services, Dr. Gottlieb worked on the implementation of the Medicare drug benefit, where he supported policy work on quality improvement and the agency's coverage process, particularly as it related to new medical technologies.